September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.
August 2016 in “Journal of Investigative Dermatology” This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.
March 2014 in “The Journal of Urology” In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.
1 citations
,
August 2016 in “Journal of Investigative Dermatology” This research reported that STAT5 activation in the dermal papilla plays a crucial role in triggering anagen entry during post-developmental hair follicle cycling.
42 citations
,
January 2019 in “Frontiers in Immunology” This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.
12 citations
,
July 2025 in “Journal of Clinical and Translational Hepatology” This review discusses how targeting TGF-β with specific inhibitors, including components from Traditional Chinese Medicine, may help reduce liver fibrosis by acting through various signaling pathways.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that the loss of Langerhans cells in lichen planopilaris scars may be linked to the downregulation of ITG αvβ6, which is not seen in other scar formation diseases.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study suggests that the outer root sheath of human hair follicles may act as a "metabolic center," capable of synthesizing glucose from lactate, which supports glycogen metabolism.
August 2016 in “Journal of Investigative Dermatology” This study found that stimulating olfactory receptor OR2AT4 in human hair follicles with Sandalore® may slow catagen development and reduce keratinocyte apoptosis, suggesting potential implications for hair growth management.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
4 citations
,
July 2025 in “Frontiers in Immunology” This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.
May 2024 in “Frontiers in Immunology” In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.
60 citations
,
September 2015 in “Expert Review of Clinical Immunology” This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.
8 citations
,
March 2014 in “American Journal of Pathology” This study found that hairless mice with homozygous mutations developed significantly more aggressive basal cell carcinomas and a heightened inflammatory response to UVB exposure compared to their haired littermates.
January 2024 in “Circulation” This commentary explores the role of PCSK9 as a target for drug development, underscoring that individuals with PCSK9 loss-of-function mutations experience significantly lowered LDL cholesterol levels and reduced coronary events, suggesting that full inactivation of PCSK9 is effective and safe.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that in alopecia areata, epidermal γδ T cells and macrophages contribute to the disease alongside CD8 T cells, with the expression of BST2 marking interferon-driven immune activation in both mouse and human skin, which decreases following treatment with the JAK inhibitor tofacitinib.
61 citations
,
December 2021 in “Frontiers in Cell and Developmental Biology” This review discusses progress in targeted therapies for vitiligo, focusing on Janus kinase inhibitors and the potential of mesenchymal stem cells, but reports no new clinical results.
26 citations
,
June 2024 in “Frontiers in Immunology” The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.
3 citations
,
September 2025 in “Frontiers in Immunology” This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.
1 citations
,
January 2025 in “Genes & Diseases” This review highlights that T cells are crucial in regulating hair follicle regeneration and their disruption can lead to alopecia, providing insights into hair disorders related to T cell immune balance and hair follicle regeneration.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.
December 2021 in “Figshare” This review discusses recent advancements in targeted therapies for vitiligo, including JAK inhibitors and mesenchymal stem cells, and highlights the need for further research.
6 citations
,
January 2023 in “International journal of molecular sciences” This review discusses the bidirectional interactions between human mast cells and CD8 T cells in the skin, particularly in the context of disorders like psoriasis, atopic dermatitis, and vitiligo, and reports no new findings.
2 citations
,
April 2025 in “Journal of Investigative Dermatology” T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.
August 2021 in “Research Square (Research Square)” This study found that BEO inhibited cell proliferation and inflammatory mediator release in a human keratinocyte acne model and reduced acne lesion severity in a rabbit model, suggesting its potential as a natural alternative to conventional acne treatments.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.
3 citations
,
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that low concentrations of CBD promoted hair follicle growth, while higher concentrations induced hair follicle regression and increased cell death in an experimental setting.
27 citations
,
November 2021 in “Scientific Reports” This study used bioinformatics to explore molecular differences in testicular and ovarian responses to SARS-CoV-2, identifying genes that could be associated with sex differences in infection outcomes.